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Abstract 
Introduction 
 Over 150 mutations have been identified in the ADAMTS13 gene in patients with congenital 
thrombotic thrombocytopenic purpura (TTP). The majority of these (86%), lead to reduced 
(<50%) secretion of mutant recombinant ADAMTS13. The mechanism by which this occurs 
has not been investigated in vitro. Two novel ADAMTS13 mutations (p.I143T and p.Y570C) 
identified in two congenital adolescence onset TTP patients were studied, to investigate their 
effects on ADAMTS13 secretion and subcellular localisation.  
Materials and Methods 
HEK293T cells were transiently transfected with wild type or mutant ADAMTS13 cDNA. 
Immunofluorescence and confocal microscopy were used to study localisation within the 
endoplasmic reticulum (ER) and Golgi. The cell proteasome and lysosomes were inhibited in 
cells stably expressing ADAMTS13 to investigate degradation of ADAMTS13 by either 
organelle.  
Results  
Both mutations severely impaired secretion and both mutants localised within the ER and 
Golgi. Proteasome inhibition led to the intracellular accumulation of both mutants, suggesting 
proteasome degradation. Lysosome inhibition on the other hand did not lead to increased 
intracellular accumulation of the mutants.  
Conclusions 
Proteasome degradation of these ADAMTS13 mutants contributed to their reduced secretion.  
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Introduction 
Thrombotic thrombocytopenic purpura (TTP) patients have an acquired or congenital 
deficiency in ADAMTS13 activity [1-3]. ADAMTS13 processes and cleaves Von Willebrand 
factor (VWF) at the Tyr1605-Met1606 peptide bond in the A2 domain [4, 5]. Its deficiency 
leads to the accumulation of ultra-large VWF (ULVWF) multimers within the circulation, 
leading to the uncontrolled formation of platelet-rich thrombi in the microcirculation and 
subsequent vessel occlusion. 
Congenital TTP patients are presently treated with plasma infusion/exchange which provides 
a source of ADAMTS13. Despite these patients typically having severely reduced 
ADAMTS13 activity, the clinical presentation and response to treatment is highly variable. 
Evidence suggests that the ADAMTS13 genotype may account for some of this heterogeneity. 
Over 150 mutations have been identified throughout the ADAMTS13 gene in patients with 
congenital TTP [1, 6-19] and relationships appear to exist between ADAMTS13 genotype, age 
of disease onset [20] and residual ADAMTS13 activity [11]. Residual ADAMTS13 activity 
in turn appears to be associated with the annual rate of TTP episodes and with the 
requirements for fresh frozen plasma prophylaxis [11].  
As residual ADAMTS13 activity appears to be associated with disease severity and with 
ADAMTS13 genotype, it is important to understand how different ADAMTS13 mutations 
affect its function. Of the mutations identified, approximately 30% have been expressed in 
vitro [7, 20-22]. These mutations affect to various degrees the secretion and activity of 
ADAMTS13 [20]. The majority (86%), lead to reduced (<50% of wild type [WT]) secretion 
of mutant recombinant ADAMTS13, suggesting misfolding of ADAMTS13 and subsequent 
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retention and degradation by the cell. The mechanism by which this may occur however has 
not been investigated in vitro. 
With this in mind we studied two novel previously uncharacterised mutations (p.I143T, 
p.Y570C) present in a homozygous form in two different congenital TTP patients [17, 23]. 
Both of these mutations are located within the N-terminal region of ADAMTS13. The 
p.I143T mutation is located within the metalloprotease domain which contains the catalytic 
site necessary for VWF cleavage [24]. The p.Y570C mutation localises within the spacer 
domain which is important for VWF binding [25-27]. The clinical history of both patients has 
been described previously [17], but in brief both presented with acute TTP during 
adolescence with undetectable ADAMTS13 activity and antigen and both receive 
prophylactic plasma infusion every three to four weeks. The effect of these mutations on 
ADAMTS13 secretion was assessed along with their effect on the intracellular localization of 
ADAMTS13. 
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Materials and Methods 
All reagents were obtained from Sigma Aldrich Chemical Company Ltd (Poole, UK) unless 
stated otherwise.  
Site directed mutagenesis  
The p.I143T (c.428T>C) and p.Y570C (c.1709A>G) ADAMTS13 mutations were introduced 
by site directed mutagenesis into a pcDNA 3.1/V5-His TOPO® vector (Life technologies, 
Paisley, UK) containing the complete ADAMTS13 cDNA as previously described [28], 
primers are available upon request.  
Transient and stable line expression 
HEK 293T cells were transiently transfected with WT or mutant ADAMTS13 cDNA as 
previously described [21], along with 1μl of pRL-TK plasmid (Promega, Southampton, UK) 
to normalize the transfection efficiency. The pRL-TK vector expresses Renilla luciferase 
which produces luminescence in the presence of its substrate (luminol). The Renilla 
luciferase assay system (Promega) was used to measure luminescence in cell lysate samples 
according to the manufacturer’s recommendations. The luminescence values were used to 
normalize antigen and activity results. DMEM media was exchanged for OptiMEM media 
just before transfection. Supernatant and cell lysate samples were harvested four days after 
transfection as previously described [28].  
Stable lines expressing WT or mutant ADAMTS13 were created as previously described 
[28]. WT and mutant supernatant from transiently transfected cells was concentrated ~20 
7 
 
fold, whereas WT and mutant supernatant from stable lines were concentrated ~100 fold 
using centrifugal filter devices with a 100kDa cut-off (Millipore UK Ltd, Livingston, UK).  
Western blotting 
For SDS-PAGE on transient transfection samples, the volumes loaded were normalized 
according to the transfection efficiency. Samples were loaded onto 4-12% Bis-Tris 
polyacrylamide gels (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) and protein was 
transferred onto 0.45μm nitrocellulose membranes (GE Healthcare, Little Chalfont, UK). A 
primary mouse anti-V5 monoclonal antibody (Life technologies) against the C-terminal V5 
tag expressed by the recombinant protein was used, followed by an ECL anti-mouse IgG 
HRP secondary antibody (GE Healthcare) for supernatant samples. For cell lysate samples 
membranes were also incubated with an anti β actin antibody loading control (Abcam, 
Cambridge, UK) after proteasome and lysosome inhibition. Membranes were developed 
using supersignal west pico chemiluminescent substrate (Fisher Scientific, Loughborough, 
UK) followed by exposure onto Amersham Hyperfilm ECL (GE Healthcare).  
ADAMTS13 antigen and activity 
ADAMTS13 antigen in supernatant samples from transiently transfected cells was measured 
using an in house ADAMTS13 antigen ELISA [29] (detection limit 3% of pooled normal 
plasma (PNP). ADAMTS13 antigen in supernatant samples from proteasome and lysosome 
inhibition experiments was measured using an Imubind ADAMTS13 antigen ELISA (Sekisui 
Diagnostics, Stamford, USA) (detection limit <60ng/ml, ~6% PNP) as one of the antibodies 
for the in house ELISA is no longer commercially available. ADAMTS13 activity in 
supernatant samples was measured using FRETS-VWF73 as substrate [30] with minor 
modifications [31] (detection limit 5% of PNP).  
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Confocal microscopy 
ADAMTS13 localisation within the cell endoplasmic reticulum (ER) and Golgi was 
investigated using immunofluorescent labelling and confocal microscopy, with antibodies 
directed against ADAMTS13 and either the ER or Golgi. HEK 293T cells transiently 
transfected with ADAMTS13 cDNA were fixed with 4% paraformaldehyde, permeabilised 
with 0.2% Triton and blocked overnight with 3% BSA containing 0.3M glycine. A chicken 
anti-V5 primary antibody (Cambridge Biosciences Ltd, Cambridge, UK) and either a mouse 
anti-GM130 (BD Biosciences, Oxford, UK, cis Golgi marker) or a mouse anti-PDI (protein 
disulphide isomerase) primary antibody (RL90 Abcam, Cambridge, UK, ER marker) was 
used. A rabbit FITC conjugated anti-chicken antibody (Life technologies) was used to detect 
the primary anti-V5 antibody. A goat Cy3 conjugated anti-mouse antibody (Millipore UK 
Ltd) was used to detect the ER/Golgi primary antibody. Cells were mounted with 
Vectashield® mounting media containing DAPI to stain for nuclei (Vector Laboratories Ltd, 
Peterborough, UK). Four to six slides were imaged per experiment, over an area of 4.84cm2. 
Cells were viewed at room temperature using a spinning disk confocal microscope (Perkin 
Elmer, Massachusetts, USA) with a Volocity acquisition system, built on a Zeiss inverted 
microscope. Images were captured using either a x63 or x100 immersion oil objective both 
with a 1.4 numerical aperture. Wavelengths for excitation vs emission were as follows: 
DAPI, 405nm vs. 455/460nm; FITC, 488nm vs. 527/555nm and Cy3 568nm vs. 615/670nm. 
Quantitation of cis Golgi colocalization 
The degree of colocalization between ADAMTS13 and the cis Golgi was quantified using 
Volocity 3D analysis software (Perkin Elmer). Clearly defined cells containing unsaturated 
voxels (throughout the Z-stack) were used for analysis. The threshold Pearson Correlation 
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Coefficient (TPCC) [32] and M1 Manders overlap colocalization coefficient (M1) [32, 33] 
were measured. For both types of analysis a ‘threshold’ was set to exclude background 
voxels, only voxels above this threshold were used for analysis. This was set by selecting a 
region containing no cells, the average voxel intensities within this region of interest plus 3 
standard deviations was then calculated by the software. Threshold values for each channel 
(FITC: 527/555nm, Cy3:515/670nm) were calculated separately. The same threshold values 
were used throughout the analysis. Images from three separate experiments were used for 
analysis. Analysis was restricted to regions containing ADAMTS13 expressing cells. The 
numbers of cells analysed were as follows: WT (n=35), p.I143T (n=29) and p.Y570C (n=52). 
Values are expressed as mean ± SEM. 
The TPCC gives a value for the correlation between the intensity distributions of the 
components (Golgi and ADAMTS13) whereas the overlap between the intensities can be 
described by the coefficient M1. Here M1 represents the sum of the intensities of the ‘red’ 
Golgi expressing voxels which are colocalized with the green ADAMTS13 voxels divided by 
the sum of the intensities of all the red (Golgi) voxels [32, 33]. 
Proteasome and lysosome inhibition  
Proteasome and lysosomes were inhibited initially in HEK 293T cells transiently transfected 
with WT or mutant ADAMTS13. However the results from this were unreliable due to 
differences in the transfection efficiency which could not be normalized using the pRL-TK 
vector. Instead HEK 293 cells stably expressing WT or mutant ADAMTS13 cDNA were 
incubated with either 10μM MG132 (Merck Chemicals, Nottingham UK), 6μM ALLN 
(Merck chemicals, prepared in DMSO), 0.1μM Bafilomycin A1 (prepared in DMSO), or 
0.1% DMSO (volume added equivalent to greatest volume of drug added). DMEM media 
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was exchanged for OptiMEM media prior to inhibitor incubation. After 5 hours cell lysate 
and supernatant samples were harvested and analysed. The ADAMTS13 antigen and activity 
measured in the supernatant in the presence of inhibitors or DMSO in a given experiment 
were expressed as a proportion of the values measured in the absence of any inhibitor or 
DMSO to normalize the results. WT and mutant values in the absence of inhibitor and DMSO 
i.e. ‘control’, was arbitrarily chosen as 1. The mean ± SEM of these normalized values are 
shown. 
Densitometry 
Densitometry was used to quantify the amount of ADAMTS13 within cell lysate samples 
after proteasome or lysosome inhibition. Image J software was used for analysis 
(http://imagej.nih.gov/ij/). 
Statistical analysis 
Unpaired two-tailed Student’s t-tests were used for analysis of differences between 
colocalisation coefficients, when the mean of WT and mutant coefficients were compared. 
For statistical analysis of normalised data (antigen, activity and densitometry), differences 
between the mean of normalised data and a hypothesised mean of 1 (i.e. no difference) were 
tested. A probability (p) value of <0.05 was considered significant. 
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Results 
Transient transfection 
ADAMTS13 was detected within the cell lysates of WT and mutant transiently transfected 
cells (Fig. 1A). No ADAMTS13 protein could be detected in the cell supernatant using 
western blotting (Fig. 1B) or an ADAMTS13 antigen ELISA and consequently no activity 
could be detected. Under similar conditions WT ADAMTS13 antigen (n=3) was 96% 
(633ng/ml) (WT and mutant transfected cells were treated in the same way, data was 
normalised to take into account the transfection efficiency, i.e. number of cells transfected, 
WT and mutant supernatant harvested after the same amount of time and both concentrated 
20 fold).  
 
Fig. 1. Western blot analysis of cell lysate and cell supernatant samples harvested from HEK293T cells 
transiently expressing WT, p.Y570C or p.I143T mutant ADAMTS13. Cell lysate (A) and supernatant (B) 
samples were harvested 96 hours after transfection.  Samples were loaded onto 4-12% Bis-Tris polyacrylamide 
gels. WT and mutant supernatant was concentrated ~20 fold for analysis. ADAMTS13 expected size ~190kDa. 
Results shown are representative of three experiments.   
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Confocal microscopy 
As both mutants appeared to be synthesised within the cell, but secreted at a severely reduced 
level, their localization within elements of the secretion pathway was investigated. WT and 
mutant ADAMTS13 localised extensively within the ER (Fig. 2A). Similarly WT 
ADAMTS13 localised within the cis Golgi (Fig. 2B), as did both mutants. However the 
degree of localization in the cis Golgi appeared to be less extensive for the mutants compared 
to WT.  
Subsequently the degree of colocalization between the cis Golgi and WT or mutant 
ADAMTS13 was quantified. TPCC values were slightly lower for the mutants (p.I143T: 
0.20±0.016; p.Y570C: 0.20±0.011) compared to WT (0.27±0.013). These differences were 
statistically significant for both the p.I143T (P=0.0009) and p.Y570C mutants (P=0.0002).  
Similarly, the mean M1 coefficient was slightly lower (p.I143T: 0.87±0.024; p.Y570C: 
0.81±0.023) for both mutants compared to WT (0.89±0.027). This difference was statistically 
significant for the p.Y570C mutant (P=0.0167) but not the p.I143T mutant (P=0.4650). 
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Fig. 2. Localisation of WT and mutant (p.I143T, p.Y570C) ADAMTS13 within the cell ER or cis Golgi as 
demonstrated by confocal microscopy. ADAMTS13 localisation in the ER (A) and cis Golgi (B) is shown. 
Cells were viewed using a Perkin Elmer Ultraview spinning disk confocal microscope at room temperature and 
images were acquired using Hamamatsu 9100-500 camera and Volocity software. Cells were mounted with 
Vectashield mounting media (Vector laboratories). FITC labelled ADAMTS13 is shown in green, Cy3 labelled 
ER or Golgi in red, DAPI labelled nuclei in blue and a merged image of all channels is shown on the far left to 
demonstrate colocalization. Cells shown in A were viewed with an original magnification of x630, numerical 
aperture 1.4, cells in B with an original magnification of x1000, numerical aperture 1.4. 
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Proteasome and lysosome inhibition  
As both mutants appeared to be synthesised within the cell, localised within the ER and to 
some extent within the Golgi, but did not appear to be secreted from the cells, we 
hypothesised that the misfolded mutants were targeted for degradation within the cell, 
thereby preventing secretion. HEK 293 cells stably expressing WT or mutant ADAMTS13 
were incubated with proteasome or lysosome inhibitors. 
Addition of the proteasome inhibitor MG132 [34] to cells stably expressing both mutants led 
to an increase in the intracellular levels of ADAMTS13 (Figure 3A, 3B), densitometric 
analysis revealed an increase of 19±2% for the p.I143T mutant and 38±10% for the p.Y570C 
mutant (Table 1). This difference was statistically significant for the p.I143T mutant. This 
increase was not observed in cells stably expressing WT ADAMTS13 (87±8% of control). 
Addition of the calpain, cathepsin, cysteine protease and proteasome inhibitor ALLN [34], 
led to a slight non-significant increase in intracellular levels for the p.I143T mutant (15±8% 
increase), but not the p.Y570C mutant (3±1% increase). Addition of the lysosome inhibitor 
Bafilomycin A1 [35] led to an increase in WT ADAMTS13 intracellular levels (24±11% 
increase). However the same increase was not observed for the two mutants (~90% of 
control). DMSO was added to the cells as a control because it was the solvent for all 
inhibitors. DMSO has been shown to act as a chaperone, aiding protein folding [36-38]. In 
the presence of DMSO intracellular levels of WT and mutant ADAMTS13 did not increase. 
The quantity of WT and mutant ADAMTS13 protein was measured in the supernatant of 
stably transfected cells in the presence of proteasome or lysosome inhibitors. In these 
experiments the supernatant was concentrated to a greater degree (~100 fold) than in the 
transient transfections; the p.I143T and particularly the p.Y570C mutant could be detected in 
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the supernatant in some of these experiments.  The ADAMTS13 antigen and activity 
measured in replicate experiments under the same conditions varied slightly, therefore the 
results were normalized. There were no consistent changes in WT ADAMTS13 antigen and 
activity measured in the supernatant after the addition of either proteasome inhibitor (MG132 
or ALLN) (antigen MG132 and ALLN: 1.1±0.2, activity MG132: 1.3±0.5, activity ALLN: 
1.2±0.2) (Fig. 4A, 4B).  
In contrast, ADAMTS13 activity levels appeared to be slightly higher in the presence of 
MG132 for the p.I143T (activity: 1.8±0.6) and particularly for the p.Y570C secretion defect 
mutant (antigen: 1.7±0.5, activity: 2.8±1.1) (Fig. 4D-F). ALLN appeared to cause a slight 
average increase in ADAMTS13 activity for the p.I143T mutant (1.4±0.4) (Fig. 4D), but not 
to the extent observed with MG132. Similarly for the p.Y570C mutant a slight increase in 
ADAMTS13 levels was observed (antigen: 1.3±0.6, activity: 1.6±1.2) (Fig.  4E, 4F) in the 
presence of ALLN, but experimental variability was higher. However these differences were 
not statistically significant. The addition of Bafilomycin A1 led to a decrease in ADAMTS13 
levels for both WT and mutant protein (Fig. 3C, 3D, 4). This difference was statistically 
significant for the p.Y570C mutant. 
DMSO led to a variable, but consistent increase in WT ADAMTS13 secretion (antigen: 
2.4±1.1, activity: 2.5±1.3). For the p.I143T mutant ADAMTS13 activity increased slightly 
with DMSO, but not to the extent observed with WT (1.5±0.4). The p.I143T antigen and 
activity values measured in these experiments were close to the detection limit of the assays 
used to measure them. In contrast for the p.Y570C mutant average antigen and activity levels 
measured in the presence of DMSO were slightly lower compared to in its absence (antigen 
0.8±0.4, activity 0.5±0.2) (Fig. 4E, 4F).  
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In the above described experiments ‘WT control’ antigen and activity levels were 
472±94ng/ml and 50±11% (mean ± SEM). Mutant ‘p.I143T control’ antigen could be 
detected in 1 of 3 experiments (60ng/ml) and ‘p.I143T control’ activity could be measured in 
two experiments, values were 7±2%. Mutant ‘p.Y570C control’ antigen and activity values 
were 258±67ng/ml and 11±5% respectively, (mean ± SEM). 
  
17 
 
 
 
 
Fig. 3. Western blot analysis of cell lysate and cell supernatant samples harvested from HEK293 cells 
stably expressing either WT or mutant ADAMTS13, incubated in the presence of proteasome or lysosome 
inhibitors. (A) WT and p.I143T cell lysates, (B) WT and p.Y570C cell lysates. (C) WT and p.I143T 
supernatant and (D) WT and p.Y570C supernatant samples were harvested ~5 hours after the addition of 
proteasome or lysosome inhibitors. HEK 293 cells stably expressing WT or mutant ADAMTS13 were incubated 
with proteasome inhibitors MG132 and ALLN or the lysosome inhibitor Bafilomycin A (Baf). The cells were 
also incubated with DMSO as a negative control. WT and mutant supernatant was concentrated ~100 fold for 
analysis. ADAMTS13 expected size ~190kDa, β actin ~42kDa. ‘Control’ indicates samples harvested from cells 
incubated in the absence of MG132, ALLN, Bafilomycin or DMSO. Western blots are representative of three 
experiments.  
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Table 1 ADAMTS13 intracellular levels in cell lysates. Densitometry was used to measure ADAMTS13 
levels in cell lysates after western blotting. Mean ± SEM are shown for each condition. Values are expressed as 
a proportion of control, arbitrarily assigned a value of 1. P values obtained after Student’s  t-test analysis are 
shown, ** <0.01 
 
 
 
 
 
 
 
  
 Condition ADAMTS13 levels P value 
W
T
 
Control 1 - 
MG132 0.87±0.08 0.187 
ALLN 0.96±0.09 0.643 
DMSO 1.03±0.10 0.774 
Bafilomycin  1.24±0.11 0.077 
I1
4
3
T
 
Control 1 - 
MG132 1.19±0.02 0.005** 
ALLN 1.15±0.08 0.149 
DMSO 1.05±0.04 0.295 
Bafilomycin  0.90±0.09 0.346 
Y
5
7
0
C
 
Control 1 - 
MG132 1.38±0.10 0.070 
ALLN 1.03±0.01 0.169 
DMSO 0.89±0.03 0.060 
Bafilomycin  0.96±0.03  0.253 
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Figure 4 ADAMTS13 antigen and activity measured in supernatant samples. Values are represented as 
mean + SEM. For analysis of WT, n=7 and for the mutants n=3. The dotted line indicates values in the absence 
of inhibitor and DMSO, i.e. 1. Half the detection limit (2.5%) was used in the analysis for samples from some 
experiments where ADAMTS13 levels for the p.I143T mutant and p.Y570C mutant were below the detection 
limit (5%), in order to calculate mean values. Student’s t-test P values are shown below each diagram, ** <0.01 
A. B. 
C. D. 
E. F. 
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Discussion  
Studies of the impact of the ADAMTS13 mutations found in congenital TTP on protein 
function are important as certain mutations may be associated with a higher degree of protein 
misfolding and/or secretion defect and have a more severe clinical phenotype. Greater 
understanding of the effect of various mutations on protein secretion and function may 
contribute to changes in patient management, prophylaxis and therapy.  
We have studied two mutations present in a homozygous state in two congenital TTP patients 
who first presented with disease during adolescence and now require plasma infusion every 
three to four weeks [17]. The p.I143T mutation present in patient one is situated within the 
metalloprotease domain, which contains the catalytic site necessary for VWF cleavage. The 
p.Y570C mutation present in patient two is located within the spacer domain, which is 
important for VWF binding [25-27]. This amino acid forms part of the surface aromatic 
cluster on the outer surface of a beta sheet [39]. In vitro expression of these mutations 
showed that they both severely impaired the secretion of ADAMTS13; no ADAMTS13 
antigen or activity could be detected in the supernatant harvested after transient transfection, 
even after concentrating ~20 fold. After concentration, WT ADAMTS13 antigen levels in 
this experimental system were similar to those found in PNP (average 96% of PNP, 
633ng/ml). These in vitro results were in agreement with the fact that ADAMTS13 antigen 
and activity were undetectable in the patient’s plasma (<1% PNP) [11, 17]. 
In order to study the intracellular processing of the mutant proteins, immunofluorescence 
confocal microscopy and proteasome/lysosome inhibition experiments were performed. 
Secretory proteins journey through the ER and Golgi where they undergo post-translational 
modification and folding. Confocal microscopy demonstrated that WT and mutant 
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ADAMTS13 localised within the ER and the cis Golgi. Localisation of the mutants in the cis 
Golgi appeared to be less extensive for the mutants and so we attempted to quantify 
differences in the localisation between the cis Golgi and WT or mutant protein. Quantitative 
analysis revealed statistical differences between WT and mutant TPCC suggesting reduced 
correlation between ADAMTS13 and the cis Golgi in the mutants. There was a significant 
difference between the M1 coefficient for WT and the p.Y570C mutant, suggesting that there 
was reduced overlap between the cis Golgi and ADAMTS13 in this mutant.  There was a 
large variation in the measured TPCC and M1 in the individual cells analysed. Perhaps to 
detect significant differences between the M1 coefficient and WT and the p.I143T mutant a 
larger number of cells would need to be analysed.  
Transiently transfected cells were used for confocal microscopy because stable line cells were 
not available at the time of analysis. One of the weaknesses of using transiently transfected 
cells is that the level of expression in each transiently transfected cell may differ. 
Consequently both high and low expressing cells were included in the quantitation analysis. 
Low expressing cells can have higher colocalization [40] possibly because the higher 
concentrations of fluorescent protein saturates high affinity sites and also occupy sites with 
lower affinities, whereas lower concentrations are confined to the high affinity sites [41]. 
This may account for the variability in the colocalization coefficients measured in different 
cells expressing the same ADAMTS13 form (i.e. WT or mutant).  
Misfolded or aggregated proteins are targeted to the proteasome or lysosomes for degradation 
[42] and so we investigated whether the mutants were degraded by either organelle. 
Proteasome inhibition using MG132 led to increased intracellular levels of both mutants. 
These results indicate that degradation of the mutants occurs in the proteasome whereas WT 
ADAMTS13 showed no significant degradation by this route. Targeting of the mutant to the 
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proteasome for degradation would prevent its secretion from the cell. ALLN is a calpain, 
cathepsin, cysteine protease and proteasome inhibitor [34]. MG132 and ALLN have been 
shown to increase intracellular levels of other proteins [43, 44], however only MG132 was 
shown to increase the mutant ADAMTS13 levels, this may be because it is a more specific 
proteasome inhibitor, compared to ALLN. 
Increased intracellular levels of WT ADAMTS13 could be measured after treating HEK 293 
cells with Bafilomycin A1, suggesting that a proportion of WT ADAMTS13 is degraded by 
lysosomes. These organelles unlike proteasomes predominantly degrade aggregated proteins 
[45] suggesting that some WT ADAMTS13 may be aggregated within the cell, this could be 
due to the high levels of ADAMTS13 expressed within the HEK 293 cells used in this 
system. The vector expressing ADAMTS13 contained a CMV promoter which would result in 
high ADAMTS13 levels, perhaps greater than physiological levels. Aggregation of WT 
ADAMTS13 may be due to the system used to express ADAMTS13 rather than this being a 
normal feature of ADAMTS13 synthesis. There did not appear to be increased levels of the 
mutants within the cell after lysosome inhibition suggesting that this organelle is not a 
significant degradation route for these proteins. It is possible that the mutant proteins were 
degraded by the proteasome before they had the opportunity to aggregate, or that the 
structural changes introduced by the mutations prevented their aggregation.  
Proteasome inhibition appeared to lead to a slight increase in the levels of the p.I143T 
mutant, however these differences were small and levels of p.I143T antigen and activity in 
these experiments were very close to the detection limit. With the p.Y570C mutant a marked 
increase in levels after the addition of MG132 could be observed. MG132 has been shown to 
activate the unfolded protein response, which leads to an increase in chaperones and folding 
enzymes to enhance the folding of misfolded proteins [46]. Furthermore perhaps by 
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inhibiting the proteasome, there was longer retention of the mutant within the ER or Golgi, 
which would have led to a greater amount of time in which the protein could fold and be 
subsequently secreted.  
Conclusions 
Both the p.I143T and p.Y570C mutations severely impaired ADAMTS13 secretion. The 
mutants were synthesised within the cell and localised within elements of the secretion 
pathway (ER and Golgi) suggesting that progress from the Golgi was impeded. The 
misfolded mutants appeared to be predominantly degraded by the proteasome as intracellular 
levels increased in the presence of proteasome inhibitors. 
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